Physician profile
Victor James Test
NPI 1144282351
$10,358.79
in general payments reported to CMS, 2019-2025
23 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $314 · 2021: $221 · 2022: $84.16 · 2023: $96.74 · 2024: $8,664 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,647 · Food and Beverage: $200 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,646.54 |
| Food and Beverage | $200.15 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $8,685.88 | 2019-2024 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $297.45 | 2019-2020 | |
| United Therapeutics Corporation | $291.43 | 2019-2024 | Orenitram, Remodulin |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2025 | |
| Intuitive Surgical, INC. | $96.74 | 2023 | Da Vinci Surgical System |
| Olympus America INC. | $95.98 | 2021 | |
| Veran Medical Technologies, INC. | $87.32 | 2019 | |
| Medivance, INC. | $86.76 | 2020 | |
| Astellas Pharma US INC | $83.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $64.89 | 2019 | |
| Baxter Healthcare | $48.78 | 2019 | |
| Genentech USA, INC. | $48.16 | 2019 | |
| Allergan, INC. | $45.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $44.88 | 2019-2025 | Airsupra |
| Philips North America LLC | $33.80 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $30.32 | 2019 | |
| Insmed, INC. | $20.70 | 2025 | Brinsupri, Arikayce |
| Aimmune Therapeutics, INC. | $20.62 | 2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.18 | 2025 | Ofev |
| Alexion Pharmaceuticals, INC. | $15.61 | 2019 | |
| Abbvie INC. | $15.29 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.82 | 2021 | |
| Csl Behring | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Test listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.